Novan to Report Second Quarter 2021 Financial Results on August 12, 2021
Novan, Inc. (Nasdaq: NOVN) will report its Q2 2021 financial results on August 12, 2021, at 8:30 a.m. ET. A conference call hosted by President and CEO Paula Brown Stafford will provide insights into the company's operational and financial performance. The call can be accessed by calling (844) 707-0661 (domestic) or (703) 318-2240 (international) with conference ID 6686508. Novan focuses on nitric oxide-based treatments, with its lead candidate SB206 targeting molluscum, aiming to meet significant medical needs.
- Company to report Q2 2021 financial results, suggesting active financial tracking.
- Lead product candidate SB206 addresses an unmet need in treating molluscum.
- None.
Company to host conference call and webcast on Thursday, August 12, 2021, at 8:30 a.m. ET
DURHAM, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2021 financial results on Thursday, August 12th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.
The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (844) 707-0661 (domestic) or (703) 318-2240 (international) and referencing conference ID: 6686508. The live webcast will be accessible on the Events page of the Investors section of the Novan website, novan.com, and will be archived for 90 days.
About Novan
Novan, Inc. is a late clinical-stage biotechnology company focused on leveraging its proprietary nitric oxide (NO) based technology platform, NITRICIL™ to generate macromolecular New Chemical Entities (NCEs) to treat multiple indications in dermatology, men’s and women’s health, infectious diseases, and various other medical conditions with significant unmet needs. The Company’s lead product candidate is SB206, a topical gel with antiviral properties, for the treatment of molluscum. The Company believes that SB206 as a topical, at-home, caregiver-applied therapy with a rapid treatment benefit, if approved, would address an important unmet medical need for the treatment of molluscum.
INVESTOR AND MEDIA CONTACT:
Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com
FAQ
When will Novan report its second quarter 2021 financial results?
How can I access the Novan conference call for Q2 2021 results?
What is the focus of Novan's lead product candidate SB206?
Who will host the Novan Q2 2021 results conference call?
